Our History

Our leadership is proud to support the visionaries, listen to the innovators and enhance the capabilities of the researchers for more than two decades.

Since our founding in 1998 as PharmaLink, IQVIA Biotech has been committed to serving small and emerging companies by offering personal attention and flexibility in addition to our extensive therapeutic experience. Our first 10 years were focused on building partnerships and investment in oncology drug development and clinical technologies.

Branded as Novella Clinical, reinforcing our commitment to move potential forward in the emerging biopharma market with a specialty focus on oncology, with the objective to help bring products to market to improve the lives of people living with cancer.

Quintiles (now IQVIA) acquired Novella Clinical in 2013 to expand insights and expertise in serving emerging biopharma and biotech companies, particularly in the areas of oncology and dermatology. 

For six years post-acquisition, Novella gained strength and expertise serving the biotech market across all therapeutic areas. In 2019, we relaunched as IQVIA Biotech, a full-service CRO, still operating as an independent business unit and exclusively serving biotech and emerging biopharma. In 2021, IQVIA Biotech expanded delivery into the JAPAC region with offices in 15 countries.

More than 25 years supporting biotech companies to bring their innovations to maximize patient impact. We are committed to continue our mission to improve patient lives for a healthier world.